Literature DB >> 23055842

Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis.

Drucy Borowitz1, Michael W Konstan, Anna O'Rourke, Morty Cohen, Leslie Hendeles, Frederick T Murray.   

Abstract

BACKGROUND: We sought to compare the differences of coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA) in healthy individuals and those with cystic fibrosis (CF) and to study the precision of CFA and CNA.
METHODS: Sixteen healthy and 23 subjects with CF and pancreatic insufficiency ate a high-fat, high-protein diet for 72 hours; stool was collected between blue food dye markers to determine CFA and CNA. Subjects with CF withheld pancreatic enzymes. Tests were repeated on 5 of the CF and 10 of the healthy subjects.
RESULTS: In healthy subjects, mean CFA was 93.5% ± 2.7%; mean CNA was 88.1% ± 5%. Median test-retest in 10 healthy subjects was +0.7% CFA (range, -8.1% to + 5.9%) and +0.9% CNA (range, -14.6% to +6.8%). For subjects with CF, mean CFA was 38.5% ± 14.7% and mean CNA was 52.2% ± 11.4%. Median test-retest change in 5 subjects with CF was -6.9% CFA (range, -19.7% to +42.8%) and +14.7% CNA (range, -6.4% to +42.8%).
CONCLUSIONS: CFA and CNA have inconsistent precision in CF. The limitations of CFA as a measure of steatorrhea correction in CF should be recognized in studies of pancreatic enzyme supplements.

Entities:  

Keywords:  cystic fibrosis; malabsorption; pancreatic enzymes; pancreatic insufficiency; pancreatic sufficiency

Year:  2007        PMID: 23055842      PMCID: PMC3462160          DOI: 10.5863/1551-6776-12.1.47

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  11 in total

1.  Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients.

Authors:  Drucy Borowitz; Christopher H Goss; Christopher Stevens; Denise Hayes; Laurie Newman; Anna O'Rourke; Michael W Konstan; Jeffrey Wagener; Richard Moss; Leslie Hendeles; David Orenstein; Richard Ahrens; Christopher M Oermann; Moira L Aitken; Thomas C Mahl; K Randall Young; Jordan Dunitz; Frederick T Murray
Journal:  Pancreas       Date:  2006-04       Impact factor: 3.327

Review 2.  Gastrointestinal outcomes and confounders in cystic fibrosis.

Authors:  Drucy Borowitz; Peter R Durie; Lane L Clarke; Steven L Werlin; Christopher J Taylor; John Semler; Robert C De Lisle; Peter Lewindon; Steven M Lichtman; Maarten Sinaasappel; Robert D Baker; Susan S Baker; Henkjan J Verkade; Mark E Lowe; Virginia A Stallings; Morteza Janghorbani; Ross Butler; James Heubi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-09       Impact factor: 2.839

3.  Steatorrhea and azotorrhea and their relation to growth and nutrition in adolescents and young adults with cystic fibrosis.

Authors:  A Lapey; J Kattwinkel; P A Di Sant'Agnese; L Laster
Journal:  J Pediatr       Date:  1974-03       Impact factor: 4.406

4.  Fecal fat and nitrogen in healthy children and in children with malabsorption or maldigestion.

Authors:  D H Shmerling; J C Forrer; A Prader
Journal:  Pediatrics       Date:  1970-11       Impact factor: 7.124

5.  A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.

Authors:  R C Stern; J D Eisenberg; J S Wagener; R Ahrens; M Rock; G doPico; D M Orenstein
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

6.  Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy.

Authors:  M W Konstan; R C Stern; J R Trout; J M Sherman; H Eigen; J S Wagener; C Duggan; M E B Wohl; P Colin
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

7.  Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis.

Authors:  Michael W Konstan; Steven M Butler; Mary Ellen B Wohl; Marcia Stoddard; Robert Matousek; Jeffrey S Wagener; Charles A Johnson; Wayne J Morgan
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

8.  Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis.

Authors:  Mary Pat Francisco; Mary H Wagner; James M Sherman; Douglas Theriaque; Ellen Bowser; Donald A Novak
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-07       Impact factor: 2.839

9.  Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis.

Authors:  Drucy Borowitz; Susan S Baker; Linda Duffy; Robert D Baker; Laura Fitzpatrick; Joyce Gyamfi; Kerry Jarembek
Journal:  J Pediatr       Date:  2004-09       Impact factor: 4.406

10.  Artificial food additive intolerance in patients with angio-oedema and urticaria.

Authors:  G Supramaniam; J O Warner
Journal:  Lancet       Date:  1986-10-18       Impact factor: 79.321

View more
  21 in total

1.  Measures of Dietary Fat and Energy Absorption in Healthy Adults.

Authors:  Hillary Bashaw; Jefferson N Brownell; Joan I Schall; Virginia A Stallings
Journal:  Pancreas       Date:  2020-07       Impact factor: 3.327

2.  Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid.

Authors:  Jill Dorsey; Donna Buckley; Suzanne Summer; Ronald J Jandacek; Therese Rider; Patrick Tso; Michael R Narkewicz; James E Heubi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-04       Impact factor: 2.839

Review 3.  Systematic review: pancreatic enzyme treatment of malabsorption associated with chronic pancreatitis.

Authors:  A K Waljee; M J Dimagno; B U Wu; P S Schoenfeld; D L Conwell
Journal:  Aliment Pharmacol Ther       Date:  2008-11-08       Impact factor: 8.171

Review 4.  Pancreatic Exocrine Insufficiency as a Complication of Gastrointestinal Surgery and the Impact of Pancreatic Enzyme Replacement Therapy.

Authors:  Adarsh Chaudhary; J Enrique Domínguez-Muñoz; Peter Layer; Markus M Lerch
Journal:  Dig Dis       Date:  2019-08-16       Impact factor: 2.404

5.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

6.  Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.

Authors:  Gavin R Graff; John McNamara; James Royall; Steven Caras; Kristin Forssmann
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency.

Authors:  Maria R Mascarenhas; John Mondick; Jeffrey S Barrett; Martha Wilson; Virginia A Stallings; Joan I Schall
Journal:  J Clin Pharmacol       Date:  2015-03-23       Impact factor: 3.126

8.  Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

Authors:  Michael W Konstan; Drucy Borowitz; Nicole Mayer-Hamblett; Carlos Milla; Leslie Hendeles; Susan Murray; Richard A Kronmal; Susan Casey; Lynn M Rose; Wayne J Morgan; Bonnie W Ramsey
Journal:  Clin Investig (Lond)       Date:  2013-08

9.  Factors Determining Optimal Fatty Acid Absorption in Preterm Infants.

Authors:  Camilia R Martin; Antonio Cheesman; Joanne Brown; Meher Makda; Allison J Kutner; Deborah DaSilva; Munir Zaman; Steven D Freedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-01       Impact factor: 2.839

10.  Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.

Authors:  Michael W Konstan; Frank J Accurso; Samya Z Nasr; Richard C Ahrens; Gavin R Graff
Journal:  Clin Investig (Lond)       Date:  2013-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.